July 2026 Cetirizine Recall: NDC and Lot Case Study for PTCE

Key Takeaways

What To Remember

• The July 2026 action covered four specified lots of cetirizine 5 mg, NDC 16571-401-10, not every cetirizine product.
• The technician discovery shows why product-integrity observation during counting can trigger a stop-and-escalate workflow.
• Match NDC and lot, quarantine affected stock, document the chain, and notify the pharmacist or supervisor.
• Do not independently diagnose the discrepancy, discard product outside procedure, or provide patient-specific advice.
• Use current FDA notices and institutional policy for real recall work because scope and instructions can change.

The Direct Answer: This Is a Product-Matching and Quarantine Case

On July 20, 2026, FDA posted a company announcement for a voluntary nationwide, consumer-level recall of four lots of Cetirizine Hydrochloride Tablets USP 5 mg because of potential cross-contamination with ranitidine. The affected presentation was a 100-tablet HDPE bottle distributed by Rising Pharma Holdings Inc., with NDC 16571-401-10. The listed lots were GY825029, GY825030, GY825031, and GY825032, all expiring 10/2028. Those exact identifiers are the center of this PTCE recall and quarantine case study.

The useful exam-prep question is not, 'What should every patient taking cetirizine do?' It is, 'How should a technician control inventory when a notice identifies a particular product and particular lots?' The defensible workflow is to inspect the notice, match the product identifiers, stop affected stock from entering dispensing workflow, quarantine it according to policy, document the action, and escalate to the pharmacist or responsible supervisor. This is study support, not an actual PTCE item or a prediction that this recall will appear on the exam.

• FDA publish date: July 20, 2026; company announcement date: July 18, 2026.
• Product: Cetirizine Hydrochloride Tablets USP 5 mg, 100-count HDPE bottle.
• NDC: 16571-401-10.
• Lots: GY825029, GY825030, GY825031, and GY825032; expiration 10/2028.
• Recall scope: voluntary nationwide recall to the consumer level.

Why the Technician Discovery Matters

The company announcement says a pharmacy technician identified a discrepancy while counting tablets during dispensing. The complaint described a red dot or multiple red-colored dots and discoloration on some tablets. That detail makes the case unusually useful for study because the quality signal appeared during an ordinary technician task, before a bottle was treated as routine stock. Visual observation did not prove the chemical cause, but it created a reason to stop and escalate a product-integrity concern.

For a PTCE-style workflow scenario, noticing an unexpected tablet appearance should not lead to an independent diagnosis, an attempt to sort out the unusual tablets, or continued dispensing from the bottle. The technician preserves the evidence and the product, prevents further use, and alerts the pharmacist or supervisor. Product complaints and recall investigations depend on accurate identifiers and documentation. The technician's value is careful observation and controlled escalation, not deciding whether a tablet is clinically safe.

Match the Recall at the Package Level

A medication name alone is too broad for this case. Cetirizine exists in multiple strengths, package configurations, manufacturers, and labeler products. The recall notice identifies a specific 5 mg product and package NDC, then narrows the scope to four lots. A bottle labeled cetirizine is not automatically affected, and a matching strength is not enough. The technician must compare the complete package information available in the notice with the physical stock and the pharmacy's inventory records.

Start with the NDC because it helps identify the labeler, product, and package configuration represented by the recalled bottle. Then verify the lot number. Also compare the product name, strength, manufacturer or distributor details, package size, and expiration date. A mismatch at one step means the item should not be casually grouped with confirmed affected stock, but uncertainty still deserves separation and pharmacist or supervisor review until the pharmacy can resolve it through its procedure.

• Do not match on the generic name alone.
• Do not match on strength alone.
• Use NDC plus lot as the primary case identifiers.
• Use package size, manufacturer or distributor, and expiration as supporting checks.
• Record what was checked and how many affected containers or units were found.

Build a Clean Quarantine Chain

Once stock is confirmed or reasonably suspected to be within scope, the immediate operational goal is to prevent dispensing. Follow the institution's method for quarantine: move the product to the designated secure area, clearly identify its status, restrict access as required, and make any inventory-system adjustment the procedure calls for. Quarantine is a controlled status, not simply placing the bottle on a nearby counter or in an unlabeled bag where it could return to usable stock.

Do not jump directly to trashing the product. The announcement states that the distributor was arranging returns of recalled product, and a pharmacy's recall procedure may require quantity reconciliation, return authorization, credits, photographs, or retention of documentation. A technician should follow the notice and institutional process for return or other disposition. The important sequence is control first, documentation next, and disposition only under authorized instructions.

Document and Escalate Without Crossing Scope

A complete record supports both safety and recall effectiveness. Depending on the setting, useful details can include the date and time the notice was received, NDC, lot, expiration, quantity located, shelf or storage areas checked, quarantine location, inventory adjustments, people notified, and the return or disposition reference. The technician should use the pharmacy's actual log, task system, or recall form rather than inventing a parallel record.

Escalation is equally important. Notify the pharmacist in charge, pharmacist on duty, inventory lead, or other supervisor named by policy. If dispensing history review, patient outreach, adverse-event handling, clinical interpretation, or communication about whether someone should continue medication is needed, those actions follow the announcement and the institution's pharmacist-led process. This article intentionally does not tell an individual patient what to do. FDA's general recall resource emphasizes checking lot numbers and following recall instructions; patient-specific questions belong with the pharmacist or other appropriate clinician.

Turn the Case Into a PTCE Reasoning Pattern

The January 2026 PTCE Content Outline expressly includes FDA requirements for medication recalls, product handling and quarantining concepts, product-integrity event reporting, and issues requiring pharmacist intervention. That makes this case relevant as a study exercise even though candidates should not expect a question about these exact lots. The durable skill is recognizing what evidence controls the workflow and which decisions require escalation.

When a practice question includes a recall notice and shelf stock, eliminate choices that rely only on the drug name, continue dispensing while someone investigates, discard product without records, or give independent patient advice. Favor the choice that accurately matches identifiers, prevents use, preserves documentation, and follows current official and institutional instructions. Recall details can change, so verify current FDA sources at the time of real work instead of relying on a study article's date stamp.

Exam Signals

What This Looks Like on the PTCE

• A notice gives an NDC, lot number, package size, manufacturer or distributor, and expiration date.
• A technician notices discoloration, unexpected markings, or another product-integrity discrepancy while counting.
• Answer choices contrast quarantine and documentation with continued dispensing or immediate unrecorded disposal.
• The scenario asks who should handle patient-specific clinical questions or determine the next communication step.
• A generic drug name appears in many products, but the notice affects only specified packages or lots.

Method

Step-by-Step Approach

1. Read the current official recall notice and the pharmacy's recall procedure.
2. Pause use of suspected stock while comparing the product name, strength, NDC, package size, manufacturer or distributor, lot, and expiration.
3. Separate and label confirmed or unresolved affected stock in the designated quarantine area.
4. Count and document the affected inventory, locations checked, people notified, and system actions required by policy.
5. Escalate to the pharmacist or responsible supervisor for dispensing-history review, communication, clinical questions, and final authorization.
6. Return or otherwise dispose of stock only according to the company announcement and institutional procedure.

Mistakes

Common Traps and Fixes

Mini Practice

PTCE-Style Practice Questions

Official References

Sources To Verify High-Risk Topics

• FDA-posted July 2026 cetirizine recall company announcement
• FDA: Understanding Drug Recalls
• PTCB PTCE Content Outline effective January 2026

Editorial Notes

How To Use This Page

This article is written for PTCE study practice and focuses on repeatable exam-prep reasoning, not patient-specific professional advice. AI tools may assist with explanations, but official references and human editorial review define the content boundaries.

For the content process, see the editorial process. For review standards, see the content review policy. For AI boundaries, see AI usage transparency. To report an issue, use contact and corrections.